.jpg?format=webp&width=780)
Immune checkpoint blockade can provide clinical benefit for patients with advanced cancer. Here, the study report durable disease control over many years following PD‐L1 blockade through induction of a viral antigen‐specific T cell response in an adult patient with recurrent respiratory papillomatosis. Although demonstrated in a single exceptional responder, these results highlight that immune checkpoint blockade may induce durable, viral antigen‐specific immunity of sufficient magnitude to control disease in patients with nonmalignant disorders.
Like
Save
Share